RESUMO
: Trauma-induced coagulopathy (TIC) occurs commonly as a second event following severe injury. We evaluated the effects of fibrinogen, recombinant factor VIIa and factor XIII on blood clotting and fibrinolysis in an in-vitro TIC model. The TIC model included hemodilution, hyperfibrinolysis, acidosis and hypothermia. The extent of clot formation and fibrinolysis was evaluated using rotational thromboelastometry. Clot strength was increased following spiking the TIC blood with either 1.0âmg/ml fibrinogen, 3.0âµg/ml recombinant factor VIIa or 2.0 IU/ml factor XIII. Maximal effect was achieved by all agents in combination approximating the extent of clot formation to those in normal blood. Fibrinolysis was inhibited by factor XIII, while the reduction was stronger using all agents together. When each of the agents used in two times lower concentrations, clot strength was near to threshold. Fibrinogen and factor XIII but not factor VIIa exerted stimulation of clot strength, whereas synergistic effect of fibrinogen and factor XIII was observed. Maximal effect was achieved combining all agents. The antifibrinolytic effect was observed only by co-administration of fibrinogen, factor XIII and factor VIIa. On the basis of our study, we suggest that stimulation of clot formation and inhibition of fibrinolysis may be achieved by combination of FG, rFVIIa an FXIII using each of them at minimal effective concentration. Taken into consideration, multifactorial TIC pathogenesis, this approach may be preferable for improving coagulopathy than separate blood spiking with the essayed factors at high concentrations.
Assuntos
Transtornos da Coagulação Sanguínea/tratamento farmacológico , Fator XIII/uso terapêutico , Fibrinogênio/uso terapêutico , Adulto , Fator XIII/farmacologia , Feminino , Fibrinogênio/farmacologia , Voluntários Saudáveis , Humanos , MasculinoRESUMO
PURPOSE: Parotidectomy is the definitive procedure for diagnosis and treatment of most parotid masses but, due to the risk of haematoma and seroma formation, has traditionally included a drain. The drain itself comes with its own risks and, in most hospitals, the need for overnight admission, which has significant cost implications (Mallon et al. Ann R Coll Surg Engl 95(4):258-262; 2013). Fibrin glue, with its haemostatic and adhesive properties, reduces the risk of collection or haematoma and therefore may negate the need for a drain. This is the first study to look at the use of ARTISS as an alternative to drains in parotidectomy. METHODS: We performed a retrospective study of all the patients who underwent a partial parotidectomy over a 4-year period from 2014 until 2018 under the same senior surgeon. Patients were divided into those that had a drain and those that had ARTISS. Their operative record, inpatient notes and clinic letters were reviewed to record information regarding length of stay, histology, complications and recurrence. RESULTS: A total of 34 patients were identified; 17 ARTISS and 17 drain patients. We showed that the mean length of stay improved significantly from 1.6 days with the drain to 0.5 days with ARTISS (Fig. 1) but without a difference in complication rate (Fig. 2), which was 5/17 (29%) in each group. CONCLUSIONS: In conclusion, parotidectomy can be undertaken safely as a day-case procedure with the application of ARTISS. This new approach to parotid surgery not only offers less morbidity for patients but also positive financial revenue for public health institutions.
Assuntos
Adesivo Tecidual de Fibrina/uso terapêutico , Fibrinogênio/farmacologia , Hematoma , Doenças Parotídeas , Complicações Pós-Operatórias/prevenção & controle , Seroma , Adulto , Procedimentos Cirúrgicos Ambulatórios/economia , Procedimentos Cirúrgicos Ambulatórios/métodos , Redução de Custos , Feminino , Hematoma/etiologia , Hematoma/prevenção & controle , Hemostáticos/farmacologia , Humanos , Masculino , Pessoa de Meia-Idade , Doenças Parotídeas/patologia , Doenças Parotídeas/cirurgia , Glândula Parótida/cirurgia , Projetos Piloto , Estudos Retrospectivos , Seroma/etiologia , Seroma/prevenção & controle , Reino UnidoRESUMO
AIM: Management of ticagrelor-induced bleeding is challenging as platelet transfusion is ineffective. An effective strategy is needed. This study aimed to investigate in vitro the efficacy of four haemostatic drugs (HDs), namely recombinant activated factor VII (rFVIIa), fibrinogen concentrate (Fib), tranexamic acid (TXA) and factor XIII concentrate (FXIII) to improve the haemostatic capacity in the presence of ticagrelor. METHODS: Blood was spiked with ticagrelor then supplemented by either HD or control. Several assays were performed: ADP-induced platelet aggregation measured by impedance aggregometry, light transmission and two global assays, thrombolastography with the platelet mapping device (TEG-PM) and a platelet-dependent thrombin generation assay (TGA). RESULTS: Ticagrelor inhibited ADP-induced platelet aggregation and decreased the clot strength maximum amplitude (MA) in TEG-PMADP. None of the HDs corrected these parameters. However, rFVIIa shortened the coagulation time R using TEG-PMthrombin and the time to peak prolonged by ticagrelor in TGA. Fib increased MAthrombin and FXIII decreased LY30. TXA had no effects. CONCLUSIONS: Whereas none of the HDs corrected ticagrelor-induced platelet inhibition, rFVIIa shortened coagulation times, Fib increased clot firmness and FXIII decreased fibrinolysis. Consequently, they may bypass ticagrelor effects by acting on fibrin formation or fibrinolysis. Further studies are needed to confirm these data in vivo.
Assuntos
Adenosina/análogos & derivados , Coagulação Sanguínea/efeitos dos fármacos , Plaquetas/efeitos dos fármacos , Hemorragia/prevenção & controle , Hemostáticos/farmacologia , Inibidores da Agregação Plaquetária/toxicidade , Adenosina/toxicidade , Plaquetas/metabolismo , Relação Dose-Resposta a Droga , Fator VIIa/farmacologia , Fibrinogênio/farmacologia , Fibrinolisina/farmacologia , Hemorragia/sangue , Hemorragia/induzido quimicamente , Humanos , Agregação Plaquetária/efeitos dos fármacos , Testes de Função Plaquetária , Proteínas Recombinantes/farmacologia , Tromboelastografia , Ticagrelor , Fatores de Tempo , Ácido Tranexâmico/farmacologiaRESUMO
Blood clotting is a natural process that can be both beneficial and life-threatening for the human body. It allows the maintenance of hemostasis after vascular injury, but it can also cause deep vein thrombosis and heart stroke. This study aimed better to understand the clotting process from a biomechanical point of view by using an acoustic method. The long-term objective is the staging of the age of clots in deep veins for therapy planning. The transient elastography method using a shear elasticity probe served to evaluate the shear wave velocity (V(S)) and shear wave attenuation (alpha(S)) of porcine whole blood during in vitro clot formation. By solving an inverse problem, it was then possible to provide images of the elasticity (mu(B)) and of the viscosity (eta(B)) from clotting blood. The time-varying elasticity and viscosity were very similar to what has been observed for the sol-gel transition of polymers. The mechanical properties of blood clot, which were modified by varying the hematocrit and by adding heparin or fibrinogen, were clearly assessed by the transient elastography technique. It is concluded that the shear elasticity probe is an appropriate tool to quantify and follow the sol-gel transition of blood during clotting.
Assuntos
Coagulação Sanguínea/fisiologia , Ultrassonografia/métodos , Animais , Anticoagulantes/farmacologia , Coagulação Sanguínea/efeitos dos fármacos , Viscosidade Sanguínea/efeitos dos fármacos , Viscosidade Sanguínea/fisiologia , Elasticidade/efeitos dos fármacos , Estudos de Avaliação como Assunto , Fibrinogênio/farmacologia , Hematócrito , Heparina/farmacologia , Reprodutibilidade dos Testes , SuínosRESUMO
PURPOSE: Sustained hemostatic function of fibrin sealant (FS) is crucial when it is used in cardiovascular surgery. The purpose of this study was to develop a model that can determine the long-term hemostatic efficacy of tissue sealants in a vascular surgery. METHODS: To determine the ability of the model to detect differences in FS performance, various concentrations of FS were prepared and tested. Tensile strength of FS clots was determined in vitro using a tensiometer. Laparotomy was performed on 49 anesthetized rabbits, and a segment of the aorta was occluded, transected, and then sutured in an end-to-end fashion with four or eight interrupted 9-O sutures. The four-suture repair was covered with FS or placebo, and blood flow restored. Spilled blood was absorbed with gauze and weighed to estimate blood loss. Four weeks after surgery the animals were euthanized and the vessels recovered for histology. RESULTS: Average tensile strength of FS clots at 120, 90, and 60 mg/ml topical fibrinogen complex (TFC) concentration was 0.42 +/- 0.07 N, with no significant difference among them. The lowest TFC concentration, 30 mg/ml, produced weaker clots than either 120 or 90 mg/ml (P < 0.05). All rabbits with four-suture anastomoses that were treated with placebo bled to death after the vessel was unclamped (n = 6). Treatment of suture line with standard FS concentration (120 mg/ml TFC, n = 8) sealed the anastomosis and prevented blood loss. Hemostasis was sustained for 4 weeks, allowing vascular healing. All rabbits with the eight-suture anastomosis survived the operation but lost 42 +/- 9.2 ml blood (n = 5). Hemostatic efficacy of FS was unchanged when TFC was diluted to 90 mg/ml (n = 6) but further dilution to 60 mg/ml with water (n = 8) produced significantly less effective clots, with an average blood loss of 5.5 +/- 7.6 ml (P < 0.05) and two fatal clot failures postoperatively. When FS was diluted to 60 mg/ml TFC with a buffer, it maintained its hemostatic strength (n = 6). Further TFC dilution to 30 mg/ml led to consistent bleeding with an average blood loss of 35.3 +/- 10.3 ml (P < 0.001, n = 6). CONCLUSIONS: The four-suture anastomosis of rabbit aorta offers a consistent and reliable method for evaluating the short- and long-term hemostatic efficacy of FS products. This model is not only able to determine the functional differences in various concentrations of FS, but it is also sensitive to detect the subtle changes in FS preparation (e.g., medium composition) that is not detected by in vitro testing.